Pan-cancer studies aim to detect the genes whose mutation is conducive to oncogenesis, as well as recurrent genomic events or aberrations between different
tumors. For these studies, it is necessary to standardize the data between multiple platforms, establishing criteria between different researchers to work on the data and present the results.
Omics data allow the rapid identification and quantification of thousands of molecules in a single experiment.
Genomics addresses the potential that certain genes will be expressed,
proteomics addresses what genes are in fact being expressed, and
metabolomics addresses what has happened in the tissue being studied. The combination of all of them gives information about the biological system.
Comparison of primary and metastatic solid tumors Pan-cancer Whole-Genome Comparison of Primary and Metastatic Solid Tumours is a comprehensive research study published in
Nature exploring genomic disparities between untreated early-stage primary tumors and treated late-stage metastatic tumors. Conducted through a harmonized analysis of 7,108 whole-genome-sequenced tumors across 23 cancer types, the study aimed to understand the impact of genomic changes on disease progression and therapy resistance.
Overview Metastatic tumors exhibited lower intratumor heterogeneity and conserved karyotypes, displaying modest increases in mutations but elevated frequencies of structural variants. The study highlighted the variable contributions of mutational footprints and identified specific genomic differences between primary and metastatic stages across various cancer types.
Methodology and Findings • The study processed 7,108 tumor genomes, harmonizing data from two unpaired primary and metastatic cohorts. • Metastatic tumors generally displayed increased clonality, while the karyotype remained mostly conserved, except for certain cancer types like prostate, thyroid, and kidney renal clear cell carcinomas. • Tumor mutation burden (TMB) exhibited moderate increases in metastatic tumors, with notable exceptions in specific cancers like breast, cervical, thyroid, prostate carcinomas, and pancreatic neuroendocrine tumors. • Mutational signature analysis revealed significant enrichment of mutational processes linked to environmental exposures and endogenous mechanisms, notably platinum-based chemotherapies, APOBEC mutagenesis, and clock-like mutational processes.
Clinical Implications and Therapeutic Resistance • The identification of treatment-associated driver alterations (TEDs) in metastatic tumors highlighted the potential implications for therapy resistance. • Several cancer types showed increased driver alterations in metastatic tumors, including genes associated with resistance to specific therapies, such as AR-activating mutations in prostate cancer and ESR1 mutations in breast cancer.
Conclusion The study demonstrated substantial genomic differences between primary and metastatic tumors across multiple cancer types. However, these differences varied considerably among cancers, influencing the genomic landscape and potential therapeutic responses. Further research and larger datasets are necessary to comprehend the complexities of tumor evolution, metastasis, and therapy resistance comprehensively.
Significance The findings offer valuable insights into tumor progression and therapy resistance mechanisms, laying the groundwork for potential personalized treatment strategies across various cancers. == Resources and databases ==